Cargando…
Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease
Background: The goal of the treatment of Alport syndrome (AS) is to delay the progression of kidney damage. The current standard of care is the use of Renin Angiotensin Aldosterone System (RAAS) blockers: angiotensin-converting enzyme inhibition (ACEi), angiotensin receptor blockade, and, recently,...
Autores principales: | Mastrangelo, Antonio, Brambilla, Marta, Romano, Giorgia, Serafinelli, Jessica, Puccio, Giuseppe, Giani, Marisa, Montini, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584724/ https://www.ncbi.nlm.nih.gov/pubmed/34768466 http://dx.doi.org/10.3390/jcm10214946 |
Ejemplares similares
-
Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood
por: Mastrangelo, Antonio, et al.
Publicado: (2020) -
Alport syndrome cold cases: Missing mutations identified by exome sequencing and functional analysis
por: Chiereghin, Chiara, et al.
Publicado: (2017) -
X-Linked Alport Syndrome in Women: Genotype and Clinical Course in 24 Cases
por: Mastrangelo, Antonio, et al.
Publicado: (2020) -
Genotype–phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome
por: Zhang, Yanqin, et al.
Publicado: (2021) -
RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)